Tamoxifen Alternative – Learn About Taking AROMASIN ® (exemestane tablets) After 2-3 Years of Tamoxifen

AROMASIN and tamoxifen

AROMASIN^® (exemestane tablets) and tamoxifen are adjuvant (AD-joo-vant) treatments. Adjuvant treatment for breast cancer is a treatment given after surgery, radiation or chemotherapy.

For postmenopausal women with ER+ early breast cancer who have been on tamoxifen for 2 to 3 years, switching to AROMASIN can help reduce the risk of recurrence more than staying on tamoxifen for 5 years. (No significant survival benefit was seen.)

Click below to see the results of the IES study.

To use this tool, you must have Flash installed on your computer. If you do not have Flash, you can download it from the Adobe Web site.

Next: Are you ready for the switch?

Ready to ask your doctor about
switching to AROMASIN?

Make the most of your appointment with a
customizable Doctor Discussion Guide.

AROMASIN^® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

AOU00471